Gilead Sciences (GILD) Q4 2025 adj. earnings decline, despite higher revenues
[ad_1] Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, has reported a decline in adjusted earnings for the fourth quarter of fiscal 2025, despite a 5% year-over-year increase in revenues. Fourth-quarter earnings, excluding one-off items, declined to $1.86 per…






